Therapeutic Asset Ratings

3,229 results matching 1 filter

91,564 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Propofol Colorectal Cancer	Fudan University	P4	B (63)
Pyrotinib Breast Cancer	Fudan University	P4	B (63)
Relatlimab Melanoma	Bristol-Myers Squibb	P4	B (63)
Ribociclib Breast Neoplasm	Eli Lilly and Company	P4	B (63)
Ribociclib Neoplasm	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P4	B (63)
Rocuronium Ion Prostate Cancer	Memorial Sloan Kettering Cancer Center	P4	B (63)
Rosuvastatin Breast Cancer	Shiraz University of Medical Sciences	P4	B (63)
Serostim Obesity Disorder	Columbia University	P4	B (63)
Sevoflurane Colorectal Cancer	Uppsala University	P4	B (63)
Silymarin Colorectal Cancer	Tanta University	P4	B (63)
Tacrolimus Lymphoma	National Cancer Institute (NCI)	P4	B (63)
Tadalafil Abdominal Obesity-Metabolic Syndrome	Kafrelsheikh University	P4	B (63)
Tadalafil Prediabetes Syndrome	Philip Kern	P4	B (63)
Telmisartan Essential Hypertension	Yuhan Corporation	P4	B (63)
Tetanus Toxoid Multiple Sclerosis	Celgene	P4	B (63)
Toripalimab Breast Cancer	Zhejiang Cancer Hospital	P4	B (63)
Tranexamic Acid Cirrhosis Of Liver	Tanta University	P4	B (63)
Vandazole Rectum Adenocarcinoma	AC Camargo Cancer Center	P4	B (63)
Vandazole Rectal Carcinoma	Helsinki University Central Hospital	P4	B (63)
(+)-Vincristine Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P4	B (63)
(+)-Vincristine Neoplasm	Pfizer	P4	B (63)
Vipivotide Tetraxetan Prostate Cancer	Mayo Clinic	P4	B (63)
Vitamin D Colorectal Cancer	Tanta University	P4	B (63)
Vortioxetine Depressive Disorder	H. Lundbeck A/S	P4	B (63)
Voxilaprevir Hepatitis C Virus Infection	Peking University People's Hospital	P4	B (63)

Showing 2426 to 2450 of 3,229 assets

PreviousPage 98 of 130Next